TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02001376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive exercise
Description: The intensive exercise group will receive moderate aerobic exercise and strengthening exercise three times a week for three months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive exercise
Description: The intensive exercise group will receive moderate aerobic exercise and strengthening exercise three times a week for three months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: The home-based exercise group will receive exercise instruction biweekly for three months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: The home-based exercise group will receive exercise instruction biweekly for three months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group live as usual
Description: Control group means no any intervention for them. The control group who with metabolic syndrome risk factors just live as usual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group live as usual
Description: Control group means no any intervention for them. The control group who with metabolic syndrome risk factors just live as usual.
Study: NCT01344876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-51602
Description: once daily during the treatment period
Study: NCT03320122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Medical direction will be provided to MTUs through a video-based conferencing unit. Each telemedicine unit includes a Rubbermaid medical grade cart with a Polycom RealPresence 500 Series high-resolution video-conferencing unit flat screen to display video. Each cart also comes with an Uninterrupted Power Supply (UPS) to make the unit mobile if needed or to properly shut it down in the event of power failure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Pediatric Physiatrist
Description: UC Davis pediatric physiatrists will drive out to the school-based MTUs to provide medical direction in person.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Non-Pediatric Physiatrist
Description: A contracted physician (i.e., a non pediatric physiatrist) would provide medical direction in person.
Study: NCT04994119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: Oral BIA 5-1058 (Zamicastat) 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: Oral BIA 5-1058 (Zamicastat) 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral Warfarin (Coumadin) 5 mg film coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral Warfarin (Coumadin) 5 mg film coated tablets
Study: NCT05816980

Intervention type: RADIATION
Group type: OTHER
Intervention: Hyperfractionated external beam radiation
Description: 40.8Gy/34 fractions (1.2Gy BID 5/7 days with minimum 6 hours interval) Concurrent capecitabine (825 mg/m2 BID 5/7 days)
Study: NCT01781494

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immobilization followed by protected range of motion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate range of motion
Study: NCT04091997

Intervention type: DIAGNOSTIC_TEST
Intervention: serum Eliza assay
Description: laparoscopy and biopsy of lesions in endometriotic patients and seum ELIZA assay of microphage migration inhibitory factor

Intervention type: DIAGNOSTIC_TEST
Intervention: serum Eliza assay
Description: laparoscopy and biopsy of lesions in endometriotic patients and seum ELIZA assay of microphage migration inhibitory factor
Study: NCT02975544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRECES programme
Description: The first unit of CRECES programme was implemented in 8 sessions. Each session was 40-50 minutes long and delivered during four weeks. Parents were provided with home-extension activities.
Study: NCT00585507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.
Study: NCT03220828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Based Distractions
Description: Technology based distractions (VR headsets)
Study: NCT03723382

Intervention type: OTHER
Intervention: SECRET structured 5 bundles of standard healthcare services
Description: THE 5 BUNDLES OF Stroke SERVICE They the mix of the services for stroke patient which are available at the SS EVT bundle: is the availability of the Endovascular services Telemedicine core bundle : is the ability to guide or guided via tele-medicine for decision making for stoke patients tPA core bundle : the availability of all infrastructure to administer tPA in the first 3 hours of onset (NNT=8) DISMAST bundle : which refer to the availability of Dysphagia detection and management ,Aspirin in hyper acute phase , The Mobilization plans and programs for the patients, anticoagulant and statin prescription for selected patients for secondary prophylaxis programs Process of care bundle : like registering patients and morphology of the disease, screening programs for risk factors , following primary prevention plans all bundles should be judged by the 8M approach
Study: NCT03505021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Levosimendan 1 mg capsule for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for levosimendan
Description: Placebo capsule for oral administration
Study: NCT01054742

Intervention type: DRUG
Intervention: Standard of Care PegIntron
Description: Commercially available PegIntron administered subcutaneously (SC) at 1.5 μg/kg weekly in accordance with the PegIntron Summary of Product Characteristics (SmPC).

Intervention type: DRUG
Intervention: Standard of Care Ribavirin
Description: Commercially available ribavirin administered orally at 800-1200 mg/day based on body weight in accordance with the ribavirin SmPC.
Study: NCT03631836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody
Description: 3 doses of Monoclonal antibody could be tested

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: fixed dose of bevacizumab (10 mg/ kg every two weeks)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Evaluate the biomarkers plasma levels during administration of drug

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)
Description: Assess antiangiogenic effects by DCE-MRI
Study: NCT04010500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: no mouthguard
Description: Control (not using mouthguard)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 'boil and bite' mouthguard
Description: KHZ058 Bicolor Mouth Guard (Shenzhen Kanghao Industrial Co. Ltd, China) will be immersed in a bowl of hot water (about 80 °C). After 50 seconds, the softened sheet will be fitted on the maxillary arch of the participant. The participant will then bite down to ensure the mouthguard stay firmly on the maxilla. After that, the mouthguard will be removed and immersed in cold water to retain its shape.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: custom-fitted mouthguard
Description: The custom-fitted mouthguards will be constructed using the dual laminated technique with two layers of ethylene vinyl acetate (EVA) thermoplastic sheets (Dentsply International Raintree Essix, Court East Sarasota, USA).
Study: NCT00218491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 1200mg N-Acetylcysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 2400mg N-Acetylcysteine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo
Study: NCT02562924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDIHONEY®
Description: MEDIHONEY® is a seminatural product with antibacterial and anti-inflammatory properties

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDIHONEY®
Description: MEDIHONEY® is a seminatural product with antibacterial and anti-inflammatory properties

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Topical steroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Topical steroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline sinus rinse
Description: 8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline sinus rinse
Description: 8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline sinus rinse
Description: 8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Post-operatively, 40 mg daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Post-operatively, 40 mg daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Post-operatively, 40 mg daily for 7 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic sinus surgery
Description: Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Description: Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Description: Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nasal saline spray
Description: saline nasal mist every hour while awake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal saline spray
Description: saline nasal mist every hour while awake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal saline spray
Description: saline nasal mist every hour while awake
Study: NCT03312660

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic group
Description: Fermented dairy product with galacto-oligosaccharides (GOS), kefiran and other metabolites resulting from the fermentation with kefir granules.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Beverage with color, flavor and nutritional composition similar to the fermented dairy product but not containing the prebiotic components.
Study: NCT01040052

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)
Description: 0.5 mL, Intramuscular
Study: NCT02475148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04523077

Intervention type: DIAGNOSTIC_TEST
Intervention: determination of thyroid hormones and antibodies
Description: TSH, fT3, fT4, anti-TPO and anti-Tg were determined from blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: determination of thyroid hormones and antibodies
Description: TSH, fT3, fT4, anti-TPO and anti-Tg were determined from blood sample
Study: NCT03065348

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral whey protein
Description: This substance is specifically formulated to target the nutritional needs of the elderly when they require increased energy and strength, such as following a fall or fracture or for the management of under nutrition and frailty. It provides 300 kcal, 20g of protein and increased levels of vitamin D, calcium. Available in vanilla, caramel and strawberry-biscuit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: This substance is a clinically proven nutritional solution for the dietary management of major elective surgery patients, to improve clinical outcomes, and reduce postoperative complications and length of hospital stay. IMPACT formulation contains omega-3 fatty acids, arginine and nucleotides, and is suitable for use as a sole source of nutrition. Oral IMPACT is a powdered sip feed that provides 303kcal per portion when reconstituted with water (74g powder plus 250ml water) and is enriched with omega-3 fatty acids, arginine, nucleotide, 3 gr of soluble fibre 321mg sodium, 402 mg potassium, 216 mg phosphate per portion.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate Drink
Description: Resource® preload™ contains the following elements:~Per portion à 50gr 47.5 gr carbohydrate, \< 10mg sodium, 190kcal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative hydration
Description: If urine specific gravity is \>1.020 then additional tap water drinking will be encouraged (1% of ideal body weight)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continous spinal anesthesia
Description: Surgery will be performed under continuous spinal anesthesia without general anesthesia
Study: NCT01677806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty
Description: Percutaneous vertebroplasty Placement of PMMA into vertebral compression fracture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative therapy
Description: Conservative therapy mainly consists of optimal pain medication. Pain management is titrated according to patients' needs, including analgesia, bed rest, and physical support (bracing).
Study: NCT00991523

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein
Description: protein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control
Study: NCT01920204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin,
Description: Midostaurin, twice daily 100 mg orally, continuously for 6 months
Study: NCT02849795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone densitometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biological analyses
Study: NCT02019407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVI, CTI block
Description: * PVI (pulmonary isolation)~* Catheter ablation of cavo-tricuspid isthmus line for treatment of atrial fibrillation~Catheter is inserted into inferior venacava (IVC) and right atrium (RA) via femoral vein. And the procedure is to block bidirectionally between inferior venacava (IVC) and the annulus of tricuspid valve (TV) by using electrical energy of catheter tip.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PVI
Description: PVI (pulmonary isolation)
Study: NCT01876407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity laser for oral mucositis

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low intensity laser for oral mucositis switch off
Description: Low intensity laser for oral mucositis switch off
Study: NCT04201925

Intervention type: PROCEDURE
Intervention: upper blepharoplasty
Description: excision of excess eyelid skin with or without strip of orbicularis muscle ; with or without upper orbital fat
Study: NCT01047774

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isolated soy protein
Description: 30-50g of protein powder daily for 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isolated milk protein
Description: 30-50g of protein powder daily for 2 weeks.
Study: NCT00276172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab 300 mg by IV infusion, every 4 weeks, for up to 24 months
Study: NCT00938314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin (hCG), then epoetin alfa (EPO)
Description: hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin (hCG), then epoetin alfa (EPO)
Description: hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin (hCG), then epoetin alfa (EPO)
Description: hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation
Study: NCT03468855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-50002 topical solution
Description: Topical Solution administered twice daily
Study: NCT02822066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroporation
Description: Effectivity and safety of irreversible electroporation for refractory neoplasms in liver and pancreas
Study: NCT04957771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervise and guide regular exercise
Description: Aerobic exercise, evaluated by cardiopulmonary exercise test, 3-5 times a week
Study: NCT02587533

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxia without dopamine
Description: Target hemoglobin oxygen saturation (SpO2) 80%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxia with dopamine
Description: Target hemoglobin oxygen saturation (SpO2) 80%. Dopamine dose 3 µg/kg/min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperoxia without dopamine
Description: Nearly complete hemoglobin oxygen saturation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperoxia with dopamine
Description: Nearly complete hemoglobin oxygen saturation. Dopamine dose 3 µg/kg/min.
Study: NCT04509778

Intervention type: OTHER
Intervention: routine clinical treatment
Description: Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
Study: NCT01150539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16-week exercise training program
Description: The primary objective of the study is to investigate the effects of a 16-week exercise training program on insulin resistance and adiposity in overweight/obese women with PCOS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group without PCOS
Description: A group of overweight/obese women without PCOS will be enrolled as a control group and will be studied only once at baseline to allow for comparisons between the two study populations.
Study: NCT02806323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga practice
Study: NCT03496090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free diet
Description: Free diet or free demand, being comparable to the normal or zero hospital diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive diet
Description: Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day.
Study: NCT01497015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: memory training
Description: 10 1-hour sessions over 6-8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: speed of processing training
Description: 10 1-hour sessions delivered over 6-8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: waitlist control
Description: Breast cancer survivors will receive the speed of processing training compact disc in the mail after study completion.
Study: NCT02227693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag
Description: E5501 (avatrombopag) 20-mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag
Description: E5501 (avatrombopag) 20-mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag
Description: E5501 (avatrombopag) 20-mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching 20-mg tablets
Study: NCT00846014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Helium-3
Description: Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
Study: NCT03955133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adverse Drug Reaction ADRe Profile for Polypharmacy
Description: PADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the British National Formulary (BNF) and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts. A full description is published (references below).
Study: NCT03329235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP
Description: platelet rich plasma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: platelet rich plasma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HA
Description: hyaluronic acid
Study: NCT02135692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab is a fully humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be supplied as a lyophilised cake in sterile vials for individual use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard of Care (SOC) will differ by participant, however it will generally include oral corticosteroids and an inhaled controller medicine (an inhaled corticosteroid plus a long acting beta agonist) and/or short acting beta agonists
Study: NCT00651092

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral nasal inferior turbinectomy
Description: the operation is performed endonasally under general or local anesthesia, the inferior turbinates are resected and removed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic submucosal resection of the inferior turbinates
Description: surgery of the inferior turbinates- endonasally with endoscopic instruments and by performing submucosal resection of the nasal turbinates